ADR News Bulletin 2024 April (Volume 26 Number 1)

Bulletin Highlights:

  • Pseudoephedrine and the rare risk of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS)
  • Analysis of adverse event reports for year 2023
  • AE Case in Focus 1: Test Yourself - What could have caused the blistering rash in this patient?
  • AE Case in Focus 2: Test Yourself - What could have caused the respiratory failure in this patient?

Click on the link below to download the issue in pdf:

ADR_News_April2024_Vol26_No1

 

New drugs approved in 2023:

Healthcare professionals are encouraged to report all serious and non-serious suspected adverse drug reactions (ADRs) with the use of new drugs. Your active participation in the ADR monitoring programme will provide valuable support to the post-marketing surveillance on drug safety.

Click on the link below to download the issue in pdf:

New Drugs Approved for 2023

 


Healthcare professional, Industry member, Therapeutic Products
Published:

Adverse Drug Reaction News Bulletins

2 Jul 2024
Doctors, dentists and pharmacists can claim continuing education points for reading each issue of the HSA ADR News Bulletin. Doctors can apply for one non-core Continuing Medical Education (CME) point under category 3A, dentists can apply for one Continuing Professional Education (CPE) point under category 3A and pharmacists can apply for one patient-care Continuing Professional Education (CPE) point under category 3A per issue of the bulletin. Each issue of the bulletin is valid for two years.